Climedo Connect
The Future of Go-To-Market Models in Pharma

November 30 2023  

CC19

Thursday, November 30 2023 

How can pharmaceutical companies effectively adapt their go-to-market models to meet the changing dynamics and evolving needs of both healthcare professionals (HCPs) and patients in the digital age? What strategies and investments are necessary to enhance the overall experience for customers while embracing a digital mindset and building the right digital capabilities?

In our Climedo Connect on November 30, Fahad Nadeem Khan (Global Commercial Director, Novo Nordisk) presented pharma's evolving go-to-market landscape along with the role of digital transformation and optimized customer experiences. We discussed:

  • Current perspectives on the biopharma go-to-market model
  • Adapting to changing dynamics and customer needs
  • Investing in digital mindset and capabilities
  • Enhancing the overall experience for customers and patients

In addition to the presentations, attendees had the chance to join various live surveys, network with other professionals and, of course, ask our expert any questions they had. 

Meet Our Speakers

Laura Dosch Climedo
Laura Dosch

Account Manager 
Climedo

As an Account Manager at Climedo, Laura accompanies pharma and medtech customers on their journey to successful clinical trials in the post-approval phase. She advises companies on the use of Climedo's modular, hybrid and integrated EDC & eCOA solutions to save time, boost efficiency and bring the best treatments to patients faster.

 

Fahan Nadeem Khan Novo Nordisk

Fahad Nadeem Khan

Global Commercial Director
Novo Nordisk

Fahad is a strategic marketer with 12+ years of experience in leading strategic brands, business plans and execution excellence. He has 6+ years of international experience in global and regional roles across many geographies. Fahad is an expert in establishing and maintaining long-term relations and creating sustainable business solutions.
 
 
 

What was on the Agenda?

  • Intro (Laura Dosch)

  • The Future of Go-To-Market Models in Pharma (Fahad Nedeem Khan)

  • Discussion and networking (all)

  • Wrap-up (Laura Dosch)

Key Takeaways

INSIGHTS

Insights into the evolving landscape of pharmaceutical go-to-market strategies and customer-centric approaches.

BEST PRACTICES
Effective strategies for adopting a digital mindset and enhancing the customer and patient experience.
NETWORKING & DISCUSSION

Networking with other industry professionals and find out how they are tackling challenges similar to yours.

⬆ Back to top

CLIMEDO

The leading European eCOA system for non-interventional studies, RWE and launch success

Climedo offers an all-in-one eCOA and EDC solution with hybrid capabilities for non-interventional studies and real-world evidence. By using a patient-centric approach and leveraging real-time data insights and visualizations around a study’s current progress, Climedo empowers its clients to better engage with healthcare professionals and other key opinion leaders (KOLs). This boosts awareness, stimulates scientific dialogue and accelerates the launch success of new medical innovations, thus reaching more patients faster.

Founded in Munich in 2017, Climedo is a leading trusted partner for pharma, medtech, CROs and academia with over 1.7 million patients enrolled to date. Learn more at www.climedo.com. 

Climedo logo
Ecosystem2023